Tremfya 100 MG/ML one-pressml
Ended Awarded Last action
- Contract number
- SPE2DR26FA4N3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,584
Award facts
- Contract value 100% obligated
- $30,583.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On February 4, 2026, the Defense Logistics Agency awarded a delivery order valued at $30,583.72 to AmerisourceBergen Drug Corp for TREMFYA 100 MG/ML (guselkumab), a biologic medication used to treat psoriasis and other inflammatory conditions. This firm fixed-price delivery order, with an ultimate completion date of February 5, 2026, was awarded on a competitive, non-set-aside basis and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a task order issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.9 billion single-award contract vehicle running through December 2031 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and supplies essential medications and medical commodities to military treatment facilities, the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's established presence within the DLA Medical Supply Chain, demonstrated through numerous competitively awarded contracts across multiple therapeutic domains, positions it as a key provider for this guselkumab delivery to support military personnel healthcare needs.
Quick answers
Who was awarded contract SPE2DR26FA4N3?
SPE2DR26FA4N3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FA4N3 worth?
The government has obligated $30,584 on SPE2DR26FA4N3.
Is contract SPE2DR26FA4N3 an order under another contract?
Yes. SPE2DR26FA4N3 is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FA4N3 competed?
The extent of competition for SPE2DR26FA4N3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award